Summary
In a double-blind study,dl-phenylalanine (150–200mg/24h) or imipramine (150–200mg/24h) was administered to 40 depressed patients (20 patients in each group) for 30 days.
Diagnoses were established according to the International Classification of Diseases (ICD). The AMP system, the Hamilton Depression Scale and the Bf-S self rating questionnaire (von Zerssen et al., 1974) were used to document psychopathological, neurologic, and somatic changes.
Twenty-seven patients (14 on imipramine, 13 on phenylalanine) completed the 30-day trial. No statistical difference could be found between these two drug treatment groups (Student'st-test) using the Hamilton Depression Scale and the Bf-S self rating questionnaire. Ratings for anxiety were significantly lower in the imipramine group on days 10 and 20, but not on day 30; in addition, sleep disturbances were more influenced by imipramine on days 1, 5, and 10, but not on days 20 and 30.
Separate analysis of psychopathological syndromes as somatic depressive syndrome and retarded depressive syndrome did not show a group difference (0.05 level of significance using a two-way analysis of variance).
It is concluded thatdl-phenylalanine might have substantial antidepressant properties. However, certain methodological considerations still warrant a careful interpretation.
Zusammenfassung
In einer Doppelblindstudie an 40 depressiven Patienten wurde unter stationären Bedingungen entwederdl-Phenylalanin (150–200 mg/die) oder Imipramin (150–200 mg/die) über einen Zeitraum von 30 Tagen appliziert.
Die psychiatrischen Diagnosen wurden gemäß der International Classification of Diseases (ICD) gestellt. Zur Dokumentation der psychopathologischen, neurologischen und somatischen Befunde wurde das AMP-System, die Bf-S-Selbsteinschätzungsskala (v. Zerssen et al., 1974) sowie die Hamilton Depressionsskala verwendet.
27 Patienten (14 unter Imipramin-, 13 unter Phenylalanintherapie) vollendeten die Studie. Mit der Bf-S-Skala und Hamilton-Skala konnten keine statistisch signifikanten (Studentst-Test) Unterschiede zwischen den beiden Behandlungsgruppen gefunden werden. Die Angst-Ratings waren auf der Hamilton-Skala in der Imipramin-Gruppe an Tag 10 und 20 niedriger als in der Phenylalanin-Gruppe, jedoch nicht mehr an Tag 30. Überdies wurden in der Imipramin-Gruppe Schlafstörungen an Tag 1, 5 und 10 günstiger beeinflußt, jedoch nicht mehr an Tag 20 und 30.
Die getrennt durchgeführte Analyse psychopathologischer Syndrome, wie z. B. somalisch-depressives Syndrom und gehemmt-depressives Syndrom, zeigten keine Gruppen-Differenz auf dem 5%-Niveau (2-Wege-Varianzanalyse).
Diese Studie gibt einen weiteren Hinweis auf mögliche antidepressive Eigenschaften vondl-Phenylalanin; gewisse melhodologische Erwägungen jedoch ermöglichen noch nicht eine eindeulige Beurteilung.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Reference
Angst, J., Battegay, R., Bente, D., Berner, P., Broeren, W., Cornu, F., Dick, P., Engelmeier, P. H., Heimann, H., Heinrich, H., Hippius, H., Poeldinger, W., Schmidlin, P., Schmitt, W., Weiss, P.: Dokumentationssystem der Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie (AMP). Arzneim.-Forsch.19, 399–405 (1969)
Baumann, U.: Angst, J.: Methodological development of the AMP system. In: Neuropsycho pharmacology, J. R. Boissier, H. Hippius, P. Pichot (Eds.). Proc. of the IX. Congress of the CINP, Paris, 7–12 July, 1974. Excerpta Medica, Amsterdam. New York: American Elsevier Publ. Comp., Inc., 1975
Beckmann, H., Dollhofer, P.: Growth hormone secretion under infusion ofdl-phenylalanine. (In preparation)
Beckmann, H., Saavedra, J. M.: Urinary excretion of phenylethylamine in depressed patients and healthy controls. (In preparation)
Beckmann, H., Strauss, A., Ludolph, E.:dl-phenylalanine in depressed patients: an open study. J. Neurol. Transm.41, 123–134 (1977)
Birkmayer, W.: Experimentelle Befunde und neue Aspekte bei extrapyramidalen Erkrankungen. Wien. Z. Nervenheilk.13, 128–139 (1966)
Boulton, A., Milward, L.: Separation, detection and quantitative analysis of urinary betaphenylethylamine. J. Chromatog.57, 287–296 (1971)
Carlsson, A., Lindquist, M.: Dependence of 5-HT and catecholamine synthesis on concentrations of precursor amino acids in rat brain. Naunyn-Schmiedeberg's Arch. Pharmacol.303, 157–164 (1978)
Cramer, H.: Zur Inkorporation von3H-Phenylalanin in Proteine der circumventriculären Organe bei Katzen und Meerschweinchen. Autoradiographische Untersuchung. Exp. Brain Res.11, 343–359 (1970)
Fischer, E., Heller, B., Nachon, M., Spatz, H.: Therapy of depression by phenylalanine. Arzneim.-Forsch.25, 132 (1975)
Fischer, E., Heller, B., Miró, A. N.:β-phenylethylamine in human urine. Arzneim.-Forsch.18, 1486 (1968)
Hamilton, M.: A rating scale for depression. J. Neurol. Neurosurg. Psychiatry23, 56–61 (1960)
ICD: International Classification of Diseases. 8. Revision. WHO, Public. No. 8921, Geneva 1974. New York-Heidelberg-Berlin: Springer 1975
Inwang, E. E., Mosnaim, A. D., Sabelli, H. C.: Isolation and characterization of phenylethylamine and phenylethanolamine from human brain. J. Neurochem.20, 1469–1473 (1973)
Jepson, J. B., Lovenberg, W., Zaltzman, P.: Amine metabolism studied in normal and phenylketonuric humans by monoamine oxidase inhibition. J. Biochem.74, 5 (1960)
Lovenberg, W., Weissbach, H., Udenfriend, S.: Aromatic L-amino acid decarboxylase. J. Biol. Chem.237, 89–97 (1962)
Morris, J. B., Beck, A.: The efficacy of antidepressant drugs. A review of research (1958–1972). Arch. Gen. Psychiatry30, 667–674 (1974)
Mosnaim, A. D., Sabelli, H. C.: Quantitative determination of the brain levels of aβ-phenylethylamine-like substance in control and drug-treated mice. Pharmacologist13, 283–294 (1971)
Mosnaim, A. D., Inwang, E. E., Sugarman, J. H., De Martini, W. J., Sabelli, H. C.: Ultraviolet spectrophotometric determination of 2-phenylethylamine in biological samples and its possible correlation with depression. Biol. Psychiat.6, 235–257 (1973)
Saavedra, J. M.: Enzymatic isotopic assay for and presence of beta-phenylethylamine in brain. J. Neurochem.22, 211–216 (1974)
Sabelli, H. C., Giardina, W. J., Mosnaim, A. D., Sabelli, N. H.: A comparison of the functional roles of norepinephrine, dopamine, and phenylethylamine in the central nervous system. Acta Physiol. Pol.24, 33–40 (1973)
Spatz, H., Heller, B., Nachon, M., Fischer, E.: Effects ofd-phenylalanine in clinical picture and phenetylaminuria in depression. Biol. Psychiatry10, 235–238 (1975)
Yariyura-Tobias, J. A., Heller, B., Spatz, H., Fischer, E.: Phenylalanine for endogenous depression. J. Orthomolec. Psychiatry3, 80–81 (1974)
Zerssen, D. von, Strian, F., Schwarz, D.: Evaluation of depressive states, especially in longitudinal studies. In: Psychological measurements in psychopharmacology. Modern problems of pharmacopsychiatry, P. Pichot, R. Olivier-Martin (Eds.), Vol. 7, pp. 189–202. Basel München-Paris: Karger 1974
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Beckmann, H., Athen, D., Olteanu, M. et al. dl-Phenylalanine versus imipramine: A double-blind controlled study. Arch. Psychiat. Nervenkr. 227, 49–58 (1979). https://doi.org/10.1007/BF00585677
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00585677